Cochrane · systematic review · CD003992
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients
Vidal, L, Ben dor, I, Paul, M, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 4 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oral compared to intravenous antibiotic therapy for febrile neutropenia in cancer patients
Population: patients with febrile neutropenia in cancer patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Oral vs intravenous antibiotic therapy | RR 0.95 [0.54, 1.68] | 9 studies · 1392 participants | Moderate Downgraded: risk of bias, imprecision |
Treatment failure Oral vs intravenous antibiotic therapy | RR 0.96 [0.86, 1.06] | 22 studies · 3142 participants | Moderate Downgraded: risk of bias |
Treatment failure ‐ per protocol analysis Oral vs intravenous antibiotic therapy | RR 0.98 [0.86, 1.11] | 22 studies · 2912 participants | Moderate Downgraded: risk of bias |
Adverse events requiring discontinuation of antibiotics Oral vs intravenous antibiotic therapy | RR 1.45 [0.61, 3.46] | 15 studies · 1823 participants | Low Downgraded: risk of bias |
Treatment failure not dt modification in update Oral vs intravenous antibiotic therapy | RR 0.95 [0.85, 1.06] | 21 studies · 3041 participants | Moderate Downgraded: risk of bias |